The first study to evaluate the clinical characteristics and outcomes of fully vaccinated patients with cancer who had breakthrough COVID-19 infections indicates they remained at high risk for hospitalization and death.
Dec 24, 2021
0
248
Mount Sinai and UC San Diego researchers have shown for the first time how mutations affecting a cellular process called RNA splicing alter cells to develop myelodysplastic syndrome (MDS) and other hematologic malignancies ...
Oct 7, 2021
0
21
(HealthDay)—There is a familial risk for hematologic malignancies, according to a study published online June 16 in Cancers.
Jul 7, 2021
0
1
(HealthDay)—Fifty-five percent of children, adolescents, and young adults with hematologic malignancies experience high-intensity end-of-life care (HI-EOLC), with an increased likelihood for those treated at medium or large ...
Jul 6, 2021
0
1
A preclinical study led by researchers at The University of Texas MD Anderson Cancer Center shows an antibody-drug conjugate (ADC) targeting surface protein MT1-MMP can act as a guided missile in eradicating osteosarcoma ...
Apr 12, 2021
0
1
People with cancers of the blood, bone marrow or lymph nodes are at an increased risk of not making protective coronavirus antibodies after COVID-19 vaccination, a new study warns.
Apr 12, 2021
0
4
Higher viral loads are associated with a greater risk of death among cancer and non-cancer patients hospitalized with coronavirus disease 2019 (COVID-19), researchers report September 15 in the journal Cancer Cell. Among ...
Sep 16, 2020
0
4
Tyrosine kinases are protein enzymes that have many functions within cells, including cell signaling, growth, and division. Sometimes these enzymes can be overactive, which helps cancer cells survive and multiply. A tyrosine ...
Jul 31, 2020
0
72
A survey of U.S. hematology-oncology fellows suggests medical school plays an important role in shaping their interest in pursuing careers in hematology, particularly when students are exposed to hematology and oncology as ...
Oct 31, 2019
0
1
With improved treatments, especially the use of anti-cancer immunotherapies, more than two-thirds of all patients diagnosed with diffuse large B-cell lymphoma (DLBCL) will survive. However, after treatment, patients are at ...
Oct 8, 2019
0
2
